AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

AstraZeneca is holding crisis talks with the Chinese authorities after the arrest of its boss in the country. The ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

South Africa has emerged as a crucial country for clinical trials in AstraZeneca’s global operations, playing a pivotal role in advancing medical research and delivering innovative treatments. Through ...

AstraZeneca is projecting that by the end of the decade ... clinical study evaluating ivonescimab as a second-line treatment of advanced non-small cell lung cancer (NSCLC). It's also conducting one ...

NHS Wales has signed a memorandum of understanding (MoU) with Illumina to expand an earlier partnership focusing on lung ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and ...

Innate's portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.